EphB4 Protein Active

• Description:

  EphB4 Protein Active_x000D_ Catalog number: B2013997_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 10 µg_x000D_ Molecular Weight or Concentration: 51 kDa_x000D_ Supplied as: N/A_x000D_ Applications: molecular tool for various biochemical applications_x000D_ Storage: ‚àí20¬∞C_x000D_ Keywords: EphB4 Protein_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Bayrak-Toydemir P, Stevenson DA. Capillary Malformation-Arteriovenous Malformation Syndrome 2011 Feb 22 [updated 2019 Sep 12]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews() [Internet]. Seattle (WA): University of Washington, Seattle; 19932023._x000D_ 2: Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, L_thi U, Barberis A, Benjamin LE, M_kinen T, Nobes CD, Adams RH. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis Nature. 2010 May 27;465(7297):483-6._x000D_ 3: Amyere M, Revencu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour JP, Martorell L, Mazereeuw-Hautier J, Pyeritz RE, Amor DJ, Bisdorff A, Blei F, Bombei H, Dompmartin A, Brooks D, Dupont J, Gonzlez-Enseat MA, Frieden I, Grard M, Kvarnung M, Hanson-Kahn AK, Hudgins L, Laut-Labrze C, McCuaig C, Metry D, Parent P, Paul C, Petit F, Phan A, Quere I, Salhi A, Turner A, Vabres P, Vicente A, Wargon O, Watanabe S, Weibel L, Wilson A, Willing M, Mulliken JB, Boon LM, Vikkula M. Germline Loss-of-Function Mutations in EPHB4 Cause a Second Form of Capillary Malformation-Arteriovenous Malformation (CM-AVM2) Deregulating RAS-MAPK Signaling Circulation. 2017 Sep 12;136(11):1037-1048._x000D_ 4: Valdivielso-Ramos M, Martin-Santiago A, Azaa JM, Hernndez-Nuez A, Vera A, Perez B, Tercedor J, Feito M, Vicente A, Prat C, Lopez-Gutierrez JC, Garnacho G, Baselga E, Roe E, Palencia S, Cordero P, Moreno R, Agudo A, de la Cueva P, Torrelo A. Capillary malformation-arteriovenous malformation syndrome: a multicentre study Clin Exp Dermatol. 2021 Mar;46(2):300-305._x000D_ 5: Ge YW, Feng K, Liu XL, Chen HF, Sun ZY, Wang CF, Liu ZQ, Wang HW, Zhang JW, Yu DG, Mao YQ. The Recombinant Protein EphB4-Fc Changes the Ti Particle-Mediated Imbalance of OPG/RANKL via EphrinB2/EphB4 Signaling Pathway and Inhibits the Release of Proinflammatory Factors In Vivo Oxid Med Cell Longev. 2020 Jun 5;2020:1404915._x000D_ 6: Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, Santos DM, Grasberger P, Ahluwalia N, Montesi SB, Shea BS, Black KE, Knipe R, Blati M, Baron M, Wu B, Fahmi H, Gandhi R, Pardo A, Selman M, Wu J, Pelletier JP, Martel-Pelletier J, Tager AM, Kapoor M. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis Nat Med. 2017 Dec;23(12):1405-1415._x000D_ 7: Cai Z, Zhang S, Wu P, Ren Q, Wei P, Hong M, Feng Y, Wong CK, Tang H, Zeng H. A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis Clin Transl Med. 2021 Feb;11(2):e309._x000D_ 8: Chen Y, Zhang H, Zhang Y. Targeting receptor tyrosine kinase EphB4 in cancer therapy Semin Cancer Biol. 2019 Jun;56:37-46._x000D_ 9: Leung K. (64)Cu-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-TNYLFSPNGPIARAW (TNYL-RAW) 2011 Sep 10 [updated 2011 Dec 15]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 20042013._x000D_ 10: Mahajan P, Bergstrom KL, Phung TL, Metry DW. The genetics of vascular birthmarks Clin Dermatol. 2022 Jul-Aug;40(4):313-321. _x000D_ _x000D_ Products Related to EphB4 Protein Active can be found at Proteins

• Short Description:

  Catalog Number: B2013997 (10 µg)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5